One of our programs, γδT cell project, was adopted as Research and Development
Support Program for Growth-Type Small and Medium Sized Enterprises (GO-TECH) 2024 by Small and Medium Enterprise Agency on June 24, and it was on the web on the same day（https://www.chubu.meti.go.jp/b31technology/sapoin/kouhyou/2024fy/saitakuitiran.pdf）. The title is “Mass Manufacturing Technology Development of Ready-Made Type γδ T Cells with Ultra-High Purity”.
（About γδT Cell）
Among human peripheral T cells, γδ T cells express unique T cell receptor (TCR)
composed with one γchain and one δ chain. Most human peripheral T cells express a TCR composed withα and β glycoprotein chains, and the ratio of γδ T cells is 1-5%. αβ T cells cause graft-versus-host disease (GVHD) while allogenic transplantation, recognizing the recipient as others and causing immune-response. It is known that ɤδ T cells are HLA independent and would not cause GVHD, and suitable for Ready-Made T cell therapy.